TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06577298

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLP-Polio high dose
Description: 1 dose of VLP-Polio vaccine (0.5ml) on day 0 for toddlers, 4 doses at 2, 3, 4 months and 12-18 months of age for infants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLP-Polio high dose
Description: 1 dose of VLP-Polio vaccine (0.5ml) on day 0 for toddlers, 4 doses at 2, 3, 4 months and 12-18 months of age for infants

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLP-Polio high dose
Description: 1 dose of VLP-Polio vaccine (0.5ml) on day 0 for toddlers, 4 doses at 2, 3, 4 months and 12-18 months of age for infants

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine Poliomyelitis Inactivated (IPV)
Description: 1 dose of IPV vaccine (0.5ml) on day 0 for toddlers, 4 doses at 2, 3, 4 months and 12-18 months of age for infants
Study: NCT05928689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counterconditioning
Description: Counterconditioning will consist of presentation of misophonia cues paired with monetary rewards.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counterconditioning
Description: Counterconditioning will consist of presentation of misophonia cues paired with monetary rewards.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet
Study: NCT06577298

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine Poliomyelitis Inactivated (IPV)
Description: 1 dose of IPV vaccine (0.5ml) on day 0 for toddlers, 4 doses at 2, 3, 4 months and 12-18 months of age for infants

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine Poliomyelitis Inactivated (IPV)
Description: 1 dose of IPV vaccine (0.5ml) on day 0 for toddlers, 4 doses at 2, 3, 4 months and 12-18 months of age for infants

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine Poliomyelitis Inactivated (IPV)
Description: 1 dose of IPV vaccine (0.5ml) on day 0 for toddlers, 4 doses at 2, 3, 4 months and 12-18 months of age for infants

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine Poliomyelitis Inactivated (IPV)
Description: 1 dose of IPV vaccine (0.5ml) on day 0 for toddlers, 4 doses at 2, 3, 4 months and 12-18 months of age for infants

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine Poliomyelitis Inactivated (IPV)
Description: 1 dose of IPV vaccine (0.5ml) on day 0 for toddlers, 4 doses at 2, 3, 4 months and 12-18 months of age for infants

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine Poliomyelitis Inactivated (IPV)
Description: 1 dose of IPV vaccine (0.5ml) on day 0 for toddlers, 4 doses at 2, 3, 4 months and 12-18 months of age for infants
Study: NCT06574932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Strategic Approach
Description: The experimental group will be engaged in multi-strategy approaches including screen time and sanity challenges, weekly screen-free days, screen time reduction goals, screen time tracking, structured daily routines, parental involvement, and monitoring, family media plans, alternative engagements, and promotion of offline social interactions.
Study: NCT06092788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTP42:KVA4 Capsule
Description: Single doses of NTP42:KVA4 administered to healthy volunteers as a capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NTP42:KVA4 Liquid
Description: Single doses of NTP42:KVA4 administered to healthy volunteers as a liquid
Study: NCT05896865

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole breast / chest wall & regional lymph node irradiation
Description: Whole breast / chest wall and corresponding regional lymph node irradiation with dose of 42.4 Gy in 16 fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal mammary or supraclavicular lymph node boost
Description: Simultaneous boost to Internal mammary or supraclavicular lymph node area with dose of total 53.6 Gy or 56.0 Gy in 16 fractions, depending on the response after neoadjuvant chemotherapy
Study: NCT06285864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interoception-based intervention
Description: Intervention will include body awareness, sensorial, and relaxation exercises, plus homework.
Study: NCT05206032

Intervention type: OTHER
Intervention: Raman spectroscopy
Description: Blood (serum or plasma) will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.

Intervention type: OTHER
Intervention: Raman spectroscopy
Description: Blood (serum or plasma) will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.

Intervention type: OTHER
Intervention: Raman spectroscopy
Description: Blood (serum or plasma) will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.
Study: NCT05967572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Research processes;
Description: 1. Before Inspection: information will be obtained and premature babies will be monitored by wearing a pulse oximeter device and their heart rate and oxygen saturation value will be recorded for control purposes. By making video recordings of each premature baby; PIPP pain score, PBIC comfort score, control oxygen saturation and peak heart rate values will be recorded 3 minutes before the ROP examination. Babies will be fed and changed at least half an hour before the examination.~2. Inspection Sequence: PIPP pain score, PBIC comfort score, control oxygen saturation and peak heart rate values will be recorded and evaluated from the video recording that continues with the start of the examination.~3. End of Inspection: Infants whose both eye examinations are completed and whose monitoring and video recording continue will be recorded and evaluated 3 minutes after the end of the examination, with PIPP pain score, PBIC comfort score, control oxygen saturation and heart rate values.
Study: NCT05701267

Intervention type: DEVICE
Intervention: MRI research
Description: 3T MRI protocol of \~1 hour

Intervention type: DEVICE
Intervention: MRI research
Description: 3T MRI protocol of \~1 hour
Study: NCT04856007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/metformin XR FDC 5/500 mg
Description: In cohort 1, subjects will be randomized to receive co-administration of a single oral dose of a 5mg dapagliflozin tablet and a 500mg metformin XR tablets (Treatment A) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 5mg dapagliflozin and 500mg metformin XR (Treatment B) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment B followed by 7 to 14 days washout and then received Treatment A on Day1 in the other treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/metformin XR FDC 10/1000 mg
Description: In cohort 2, subjects will be randomized to receive co-administration of a single oral dose of a 10mg dapagliflozin tablet and two 500mg metformin XR tablets (Treatment C) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 10mg dapagliflozin and 1000mg metformin XR (Treatment D) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment D followed by 7 to 14 days washout and then received Treatment C on Day1 in the other treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg + Metformin 500 mg XR
Description: In cohort 1, subjects will be randomized to receive co-administration of a single oral dose of a 5mg dapagliflozin tablet and a 500mg metformin XR tablets (Treatment A) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 5mg dapagliflozin and 500mg metformin XR (Treatment B) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment B followed by 7 to 14 days washout and then received Treatment A on Day1 in the other treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg + Metformin 1000 mg XR
Description: In cohort 2, subjects will be randomized to receive co-administration of a single oral dose of a 10mg dapagliflozin tablet and two 500mg metformin XR tablets (Treatment C) followed by 7 to 14 days washout and then receive single FDC tablet consisting of 10mg dapagliflozin and 1000mg metformin XR (Treatment D) on Day 1 in one treatment sequence. Or subjects will be randomized to be administered the Treatment D followed by 7 to 14 days washout and then received Treatment C on Day1 in the other treatment sequence.
Study: NCT06575504

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonographical examination
Description: Study size and Doppler / blood flow / of the suprarenal gland
Study: NCT06574672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embedded Hospice and Palliative Care Practitioner
Description: The hospice and palliative care practitioner will be embedded in one medical intensive care unit for the first half of the study timeframe, after which the practitioner will expand to both medical intensive care units. While active in a medical intensive care unit, the practitioner will proactively trigger palliative care consultations based on clinical criteria and estimated mortality risk, in addition to providing immediate availability for standard-of-care hospice or palliative care consultations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Embedded Hospice and Palliative Care Practitioner (Group Effect)
Description: While the hospice and palliative care practitioner is active in one medical intensive care unit with respect to triggering consultations, the other medical intensive care unit can still utilize the practitioner's services for standard-of-care hospice or palliative care consultations.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: None (Historical)
Description: This control arm includes historical patients admitted to the medical intensive care units prior to the study's enrollment timeframe.
Study: NCT06574776

Intervention type: OTHER
Intervention: Observation and collecting data
Description: In that single cohort we will collect data on MDRO infection and colonization prevalence, clinical characteristics, infections, causative organisms and mortality.
Study: NCT06144164

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate Lymphatic Reconstruction
Description: Immediate Lymphatic Reconstruction will happen at the time of Axillary Lymph Node Dissection

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Volumetric arm measurements
Description: Volumetric arm measurements will occur at each in-person postoperative visit time points.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lymphatic massage
Description: Participants will begin self-directed lymphatic massage 24 to 48 h after surgery and will continue to do lymphatic massage 3 times a week for 3 months after surgery or until 3 months after any adjuvant treatments (chemotherapy, radiation, etc.) are completed
Study: NCT05624658

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combined Lipid-lowering Therapy
Description: the effect of high-dose combined lipid-lowering therapy (statins+ezetimibe vs statins+PCSK9 inhibitors) on the vulnerability characteristics of atherosclerotic plaques assessed using multimodal imaging (coronary artery computed tomography and optical coherence tomography), as well as biomarkers in patients with acute coronary syndrome for 52 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Combined Lipid-lowering Therapy
Description: the effect of high-dose combined lipid-lowering therapy (statins+ezetimibe vs statins+PCSK9 inhibitors) on the vulnerability characteristics of atherosclerotic plaques assessed using multimodal imaging (coronary artery computed tomography and optical coherence tomography), as well as biomarkers in patients with acute coronary syndrome for 52 weeks.
Study: NCT06150027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic referral to a palliative care team
Description: Patients randomized in the experimental arm will be systematically referred to a palliative care team.~A follow-up in palliative care will be initiated for all within a maximum of 15 days after the date of randomization.
Study: NCT04753840

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs
Description: One of ACEI / ARB, beta blocker, calcium channel blocker, diuretic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning（RIPC）
Description: 40 minutes per day, 10 minutes as a cycle (cuff inflated to 200 mmHg and maintained for 5 minutes, then deflated for 5 minutes to start the next cycle)， a total of 4 cycles.
Study: NCT06144164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Range of motion exercises
Description: Participants will begin self-directed lymphatic massage 24 to 48 h after surgery and will continue to do lymphatic massage 3 times a week for 3 months after surgery or until 3 months after any adjuvant treatments (chemotherapy, radiation, etc.) are completed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression garment use
Description: Participants will use compression garments 24 to 48 h after surgery and will continue daily use for at least 8 h a day for 3 months or until 3 months after any adjuvant treatments are completed
Study: NCT04753840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Description: Such as changing dietary habits, smoking cessation and alcohol restriction, exercise and so on.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Description: Such as changing dietary habits, smoking cessation and alcohol restriction, exercise and so on.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: lifestyle intervention
Description: Such as changing dietary habits, smoking cessation and alcohol restriction, exercise and so on.
Study: NCT05063279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Description: Progressive resistance training, performed with a target number of repetitions of 10 per set. Sets are performed to exhaustion, and external load will be adjusted to meet the target number of repetitions.
Study: NCT05918926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Individualised remote exercise intervention
Study: NCT06038565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RAM cannula ventilator CPAP
Description: RAM cannula ventilator CPAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RAM cannula ventilator CPAP
Description: RAM cannula ventilator CPAP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusive interface bubble CPAP
Description: Occlusive interface bubble CPAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusive interface bubble CPAP
Description: Occlusive interface bubble CPAP
Study: NCT05411458

Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic and Relaxation Exercises
Description: 12-week treatment program; A - 6 weeks of aerobic exercise (AE) (outdoor walking program) 6 week program B - Jacobson Progressive Relaxation Exercises (JIGE) (done by patients at home). The 6-week B program (JIGE) was applied in addition to the aerobic exercise (AE) program.~Aerobic exercise (AE) program:The aerobic training program was applied as walking for 40 minutes in the open air. The Rating of Perceived Exertion (RPE) Borg Scale (6-20) was used to determine the walking pace, and they were asked to walk according to the light (11-12) level according to the Borg scale.~An exercise program is 30-45 minutes, and the applications are done every other day and 3 days a week.The treatment programs started with the evaluation of the cases by the physiotherapist and are followed up using the Telerehabilitation method. At the beginning of each week, the patients were called and checked, and their exercise treatments were completed at the end of 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic and Relaxation Exercises
Description: 12-week treatment program; A - 6 weeks of aerobic exercise (AE) (outdoor walking program) 6 week program B - Jacobson Progressive Relaxation Exercises (JIGE) (done by patients at home). The 6-week B program (JIGE) was applied in addition to the aerobic exercise (AE) program.~Aerobic exercise (AE) program:The aerobic training program was applied as walking for 40 minutes in the open air. The Rating of Perceived Exertion (RPE) Borg Scale (6-20) was used to determine the walking pace, and they were asked to walk according to the light (11-12) level according to the Borg scale.~An exercise program is 30-45 minutes, and the applications are done every other day and 3 days a week.The treatment programs started with the evaluation of the cases by the physiotherapist and are followed up using the Telerehabilitation method. At the beginning of each week, the patients were called and checked, and their exercise treatments were completed at the end of 12 weeks.
Study: NCT05205265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rivet Shunt
Description: The Rivet Shunt device will be implanted via a percutaneous, transcatheter approach
Study: NCT06090825

Intervention type: OTHER
Intervention: Observational study
Description: Observational study
Study: NCT05984901

Intervention type: DEVICE
Group type: OTHER
Intervention: The continuous ambulatory vestibular assessment (CAVA) system
Description: The CAVA trial is a diagnostic accuracy multicentre device trial which aims to quantify the extent to which the CAVA system can differentiate three common inner-ear causes of dizziness: Ménière's disease, vestibular migraine and Benign Paroxysmal Positional Vertigo (BPPV).~The CAVA device is composed of two components: a set of bespoke single-use sensor arrays that adhere to the left and right side of the participant's face; and a small reusable module fitting over the ear that contains a battery, microcomputer data storage facility and connection ports for the arrays. The CAVA device will be worn by all participants for 30 days with the aim of capturing eye movement data during a dizzy attack.~The first objective is to develop an algorithm that can discriminate between the 3 listed dizziness conditions. The second is to quantify the financial and patient benefits of deployment in the NHS. The final objective is to expedite a plan to deploy the system in the NHS.
Study: NCT05776264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Condition
Description: During one of the sessions, participants will listen to music while walking on the treadmill for 10 minutes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Podcast Condition
Description: During one of the sessions, participant will listen to a podcast for 10 minutes while walking on the treadmill.
Study: NCT06163885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stoma care education with flipped classroom
Description: Flipped classroom model will use for stoma care education.These training models will explore which of them will be most useful for participants in the acquisition of stoma care skills and knowledge. It will also monitor whether there is any change in the level of academic self-efficacy of nursing students who follow these educational models.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stoma care education with peer-supported education model
Description: Peer-supported education model will use for stoma care education.These training models will explore which of them will be most useful for participants in the acquisition of stoma care skills and knowledge. It will also monitor whether there is any change in the level of academic self-efficacy of nursing students who follow these educational models.
Study: NCT05577988

Intervention type: OTHER
Group type: OTHER
Intervention: single-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing.
Description: * Individuals without genetic loss of function to metabolize clopidogrel: stop DAPT and switch to a single antiplatelet therapy by clopidogrel.~* Individuals with genetic loss of function to metabolize clopidogrel (\*2/\*3, 1/\*3, \*2/\*2, \*1/\*2): stop potent P2Y12 inhibitor and treat with a single antiplatelet therapy by aspirin.~* Individuals with fast metabolization of clopidogrel (\*1/\*17 or \*17/\*17): stop potent P2Y12 inhibitor and treat with a single antiplatelet therapy by aspirin.
Study: NCT05697354

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation using interactive tablet
Description: the cognitive rehabilitation exercises will be administered using the Khymeia VRRS Home Tablet. Patients will be asked to actively carry out exercises focused on the following cognitive functions: language, attention, executive functions, verbal memory, visuo-spatial memory.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation using smartphone App Medico Amico
Description: the cognitive rehabilitation exercises will be administered through patients' smartphone using the Medico Amico App. Patients will be asked to observe and concentrate on exercises focused on the following cognitive functions: language, attention, executive functions, verbal memory, visuo-spatial memory.
Study: NCT05748925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapagliflozin
Description: The patients will be randomized into two groups Study group: will receive SGLT2i as add on drug or replace another drug according to the patient clinical situation, Dapagliflozin 10 mg will be used once daily with or without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Control group: will be maintained on their medication
Study: NCT05046080

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records reviewed

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03568292

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus Rift Headset
Description: Subject wears headset for virtual reality intervention during bone marrow biopsy or lumbar puncture procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies